JP2017504611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504611A5 JP2017504611A5 JP2016542139A JP2016542139A JP2017504611A5 JP 2017504611 A5 JP2017504611 A5 JP 2017504611A5 JP 2016542139 A JP2016542139 A JP 2016542139A JP 2016542139 A JP2016542139 A JP 2016542139A JP 2017504611 A5 JP2017504611 A5 JP 2017504611A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutically acceptable
- combination
- cancer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 29
- 150000003839 salts Chemical class 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 17
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 16
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 16
- 239000003112 inhibitor Substances 0.000 claims 10
- 229940118537 p53 inhibitor Drugs 0.000 claims 9
- 239000013543 active substance Substances 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- -1 5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl Chemical group 0.000 claims 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 1
- 101150012716 CDK1 gene Proteins 0.000 claims 1
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920032P | 2013-12-23 | 2013-12-23 | |
| US61/920,032 | 2013-12-23 | ||
| US201461948323P | 2014-03-05 | 2014-03-05 | |
| US61/948,323 | 2014-03-05 | ||
| PCT/IB2014/067139 WO2015097621A2 (en) | 2013-12-23 | 2014-12-19 | Pharmaceutical combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504611A JP2017504611A (ja) | 2017-02-09 |
| JP2017504611A5 true JP2017504611A5 (enExample) | 2018-02-01 |
| JP6532878B2 JP6532878B2 (ja) | 2019-06-19 |
Family
ID=52278689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542139A Expired - Fee Related JP6532878B2 (ja) | 2013-12-23 | 2014-12-19 | 組合せ医薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20160339023A1 (enExample) |
| EP (1) | EP3086810A2 (enExample) |
| JP (1) | JP6532878B2 (enExample) |
| KR (1) | KR20160100975A (enExample) |
| CN (1) | CN105848682A (enExample) |
| AU (2) | AU2014372166B2 (enExample) |
| BR (1) | BR112016012506A8 (enExample) |
| CA (1) | CA2934866A1 (enExample) |
| MX (1) | MX2016008362A (enExample) |
| RU (1) | RU2016129953A (enExample) |
| TW (1) | TW201609100A (enExample) |
| WO (1) | WO2015097621A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2939778C (en) | 2007-01-31 | 2019-01-29 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| CA2682174C (en) | 2007-03-28 | 2021-04-06 | President And Fellows Of Harvard College | Stitched polypeptides |
| KR20130099938A (ko) | 2010-08-13 | 2013-09-06 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| CN104039342A (zh) | 2011-10-18 | 2014-09-10 | 爱勒让治疗公司 | 拟肽大环化合物 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| NZ627528A (en) | 2012-02-15 | 2016-05-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| SG11201503052RA (en) | 2012-11-01 | 2015-05-28 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| MX2017003797A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| MX389354B (es) | 2014-09-24 | 2025-03-20 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y formulaciones de los mismos. |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP2018526430A (ja) | 2015-07-10 | 2018-09-13 | アルヴィナス・インコーポレイテッド | タンパク質分解のｍｄｍ２系修飾因子および関連の使用方法 |
| MX2018001903A (es) * | 2015-08-14 | 2018-06-20 | Novartis Ag | Inhibidores de mdm2 para el tratamiento de melanoma uveal. |
| ES2962460T3 (es) | 2015-08-28 | 2024-03-19 | Novartis Ag | Inhibidores de mdm2 y combinaciones de estos |
| JP6911019B2 (ja) | 2016-05-17 | 2021-07-28 | 公益財団法人がん研究会 | Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬 |
| US20200268728A1 (en) * | 2016-12-20 | 2020-08-27 | Sumitomo Dainippon Pharma Co., Ltd. | Drug targeting cancer stem cell |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US20190343836A1 (en) * | 2017-01-10 | 2019-11-14 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| EP3600326B1 (en) * | 2017-03-31 | 2023-01-25 | Novartis AG | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
| JP7358372B2 (ja) * | 2018-03-12 | 2023-10-10 | 羅欣薬業（上海）有限公司 | イミダゾピロロン化合物及びその使用 |
| WO2019182936A1 (en) * | 2018-03-19 | 2019-09-26 | Ariad Pharmaceuticals, Inc. | Methods of treating cancer in pediatric patients |
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| AU2024212035A1 (en) | 2023-01-26 | 2025-08-14 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2024353A2 (en) | 2006-03-16 | 2009-02-18 | Pfizer Products Inc. | Pyrazole compounds |
| KR101364277B1 (ko) * | 2006-12-08 | 2014-02-21 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
| ME00811B (me) * | 2006-12-08 | 2012-03-20 | Novartis Ag | JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE |
| KR101238585B1 (ko) * | 2008-04-07 | 2013-02-28 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| MY155535A (en) | 2008-05-23 | 2015-10-30 | Novartis Ag | Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors |
| KR101353857B1 (ko) * | 2008-08-22 | 2014-01-21 | 노파르티스 아게 | Ｃｄｋ 억제제로서 피롤로피리미딘 화합물 |
| JO3002B1 (ar) * | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| CU24130B1 (es) * | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| UA108746C2 (xx) * | 2009-12-22 | 2015-06-10 | Заміщені ізохінолінони та хіназолінони | |
| BR112013019643B1 (pt) * | 2011-02-02 | 2022-04-19 | Novartis Ag | Uso de inibidores de álcali |
| AU2012240240A1 (en) * | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| US8815926B2 (en) * | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| AU2013341271A1 (en) * | 2012-11-07 | 2015-05-14 | Novartis Ag | Combination therapy |
-
2014
- 2014-12-19 RU RU2016129953A patent/RU2016129953A/ru not_active Application Discontinuation
- 2014-12-19 CA CA2934866A patent/CA2934866A1/en not_active Abandoned
- 2014-12-19 BR BR112016012506A patent/BR112016012506A8/pt not_active IP Right Cessation
- 2014-12-19 MX MX2016008362A patent/MX2016008362A/es unknown
- 2014-12-19 US US15/107,232 patent/US20160339023A1/en not_active Abandoned
- 2014-12-19 KR KR1020167016376A patent/KR20160100975A/ko not_active Withdrawn
- 2014-12-19 WO PCT/IB2014/067139 patent/WO2015097621A2/en not_active Ceased
- 2014-12-19 JP JP2016542139A patent/JP6532878B2/ja not_active Expired - Fee Related
- 2014-12-19 CN CN201480070695.9A patent/CN105848682A/zh active Pending
- 2014-12-19 EP EP14821861.3A patent/EP3086810A2/en not_active Withdrawn
- 2014-12-19 AU AU2014372166A patent/AU2014372166B2/en not_active Ceased
- 2014-12-23 TW TW103145083A patent/TW201609100A/zh unknown
-
2017
- 2017-10-09 AU AU2017245295A patent/AU2017245295A1/en not_active Withdrawn
-
2018
- 2018-01-25 US US15/879,942 patent/US20180185365A1/en not_active Abandoned
- 2018-11-05 US US16/180,078 patent/US20190134033A1/en not_active Abandoned